SEZI Share Price Performance
SEK 3.60
-3.57 (-49.79%)
62.1% undervalued intrinsic discount
SEK 9.50
Fair Value
Price SEK 3.60
AnalystConsensusTarget SEK 9.50
Fair ValueSEK 9.50
Share Pricen/a
Senzime AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
SEZI Community Narratives
AN
Fair Value
·Fair Value SEK 9.5 62.1% undervalued intrinsic discount
US And European Guidelines Will Expand Neuromuscular Monitoring Adoption Worldwide
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US And European Guidelines Will Expand Neuromuscular Monitoring Adoption Worldwide
Hospitals in the U.S. and Europe are starting to treat neuromuscular monitoring as a must-have during surgery, and that shift could make Senzime’s TetraGraph system a more common fixture in operating rooms. The upside hinges on turning more installs into steady sensor sales while proving it can grow beyond the U.S. and protect margins from tariffs and currency swings.Read more
AN
SEK 9.5
62.1% undervalued intrinsic discount
Fair Value
Profit Margin
10.59%
Future PE
46.8x
Price in 2029
SEK 11.2
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
SEZI: Expanded US Hospital Access Will Support Future Earnings Power
Fair Value: SEK 9.5 62.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Senzime AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 29, 2026
- -0.71
- 33.02%
- -109.30%
- 2.8%
About SEZI
- Founded
- 1999
- Employees
- 59
- CEO
- WebsiteView website
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe. The company has a strategic connectivity and licensing agreement with Masimo that grants Senzime the rights to use some of Masimo’s intellectual property; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.
